ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
TP53 Loss Elevates NF-κB-IFN-β-MHC-Ia Signaling to Promote NK Cell Resistance in Osteosarcoma.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
TP53 inactivation is a key event in osteosarcoma (OS) development and underlies its aggressiveness, yet its role in tumor-immune interactions remains poorly understood. Here, we investigate how p53 loss alters osteosarcoma susceptibility to natural killer (NK) cell-mediated cytotoxicity using OS cell lines and stem cell-derived OS-associated models. We found that TP53 loss in human osteosarcoma cell lines dysregulates NK cell regulatory ligands, specifically upregulating MHC-Ia to confer resistance to NK cell killing. Single-cell RNA sequencing of clinical specimens reveals mesenchymal stem cells (MSCs) is associated with OS development. Using human embryonic stem cell (hESC)-derived MSCs, the study shows that TP53 loss also drives MHC-Ia overexpression and NK cell resistance via activation of the cytosolic dsDNA-NF-κB-IFN-β axis. Syngeneic mouse models confirmed that p53 loss results in more aggressive tumors with reduced NK cell infiltration than wild-type controls. Clinically, impaired p53 function correlates with elevated MHC-Ia expression and type I IFN signaling. These findings uncover that a TP53 loss-triggered NF-κB-IFN-β-MHC-Ia axis contributes to NK cell resistance in OS development and highlight its potential as a critical therapeutic target for early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.